CoChat

Augmentation with Atypical Antipsychotics for Depression: A Review of Evidence‐Based Support from the Medical Literature

Wright, Bradley M., Eiland, Edward H., Lorenz, Raymond · 2013 · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Cited by 84

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Major depressive disorder ( MDD ) is a chronic mental illness that affects an estimated 5–26% of adults at some time in their lives. Treatment is often started as pharmacotherapy using a single drug such as a selective serotonin reuptake inhibitor. If a patient fails to respond adequately to the initial antidepressant, typically three pharmacotherapy options are available to the practitioner. The dose of the current therapy can be maximized, a change can be made to a different drug, or the current regimen can be augmented with another drug. Atypical antipsychotics have recently become a major focus for augmentation of traditional antidepressant therapy. This review summarizes the evidence for efficacy and safety of augmenting treatment‐refractory or treatment‐resistant depression with atypical antipsychotics. The National Library of Medicine's MEDLINE database was searched for all English‐language articles published from January 1966–December 2011 describing the use of atypical antipsychotics in treatment‐resistant depression. The literature retrieved was limited to case series, open‐label trials, and randomized controlled trials ( RCT ). Studies of bipolar depression, psychotic depression, or studies conducted in children and adolescents were excluded. Thirty‐five studies using atypical antipsychotics for augmentation treatment of depression were included in this analysis. Trials were identified for aripiprazole (six open‐label; three RCT ), clozapine (one case series), olanzapine (three open‐label, including two case series; four RCT ), quetiapine (four open‐label; five RCT ), risperidone (two open‐label; five RCT ), and ziprasidone (two open‐label). The atypical antipsychotics may be effective as adjunctive therapy in MDD ; however, their adverse effect profile may be unfavorable to some patients. Trying at least one alternative treatment strategy after an initial antidepressant is indicated before augmentation is implemented with these agents. If atypical antipsychotics are used, safety and efficacy should be frequently reassessed and dosage should be individualized.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/phar.1204

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

Metadata

Authors
Wright, B. M., Eiland, E. H., & Lorenz, R.
Venue
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Publisher
Wiley
Published
2013-03
Volume
33
Issue
3
Pages
344-359
ISSN
  • 0277-0008 (ISSN-L)
  • 1875-9114
OpenAlex
W1998648170
Cited by
84
References
16
FWCI
6.95
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.